Telaprevir in genotype 3 HCV
Research type
Research Study
Full title
Telaprevir in patients with genotype 3 HCV : pilot clinical study to evaluate efficacy and predictability of therapy in patients who have failed to respond to pegylated interferon and ribavirin
IRAS ID
127802
Contact name
Graham Foster
Contact email
Sponsor organisation
Queen Mary University of London
Eudract number
2013-003729-27
ISRCTN Number
n/a
Research summary
People with genotype 3 hepatitis C who have advanced liver disease (cirrhosis) have a very high chance of developing fatal complications of their disease unless they receive effective treatment. Unfortunately the best drugs that are currently available to treat genotype 3 hepatitis C (pegylated interferon and ribavirin) only work in about 50% of patients with advanced liver disease and therefore a large number of patients who have failed treatment are waiting for new, better drugs. We have no treatments available for these patients. Telaprevir is a new drug that is licensed to treat genotype 1 hepatitis C and which works very well in these patients. In patients with genotype 3 hepatitis C small scale trials and laboratory studies show that some patients do respond quite well and others respond a little bit when given telaprevir. In people who have exhausted all other treatment options we speculate that telaprevir treatment may help some people by clearing their infection. The purpose of this study is to see if telaprevir can help these patients and to determine if we can predict in advance which people can be helped.
REC name
London - Riverside Research Ethics Committee
REC reference
13/LO/1473
Date of REC Opinion
16 Oct 2013
REC opinion
Favourable Opinion